Center for Clinical Studies

1. Novartis Pharmaceuticals Corporation $941,329 31 payments
2. Incyte Corporation $773,216 401 payments
3. Amgen Inc. $767,555 28 payments
4. Ucb SA $481,588 34 payments
5. E.R. Squibb & Sons, L.L.C. $426,157 21 payments
6. Sun Pharmaceutical Industries Inc. $232,496 68 payments
7. Celgene Corporation $166,003 7 payments
8. AbbVie, Inc. $106,009 33 payments
9. Argenx US, Inc. $41,353 9 payments
10. Merck Sharp & Dohme Corporation $25,846 10 payments

1. Multicenter Randomized Double Blind Placebo Controlled 52 Week Study to Demonstrate the Efficacy Safety and Tolerability of Secukinumab Injections With 2 ML Auto Injectors 300 MG in Adult Subjects With Plaque Psoriasis $404,054 3 payments
2. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $353,021 22 payments
3. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $229,862 18 payments
4. A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp $228,297 26 payments
5. A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $224,353 3 payments
6. PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell carcinoma-a window of opportunity trial $212,443 16 payments
7. Psor-025/20200063 (Discreet) $175,337 2 payments
8. A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) $150,301 4 payments
9. A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 MG Over 32 Weeks in Adult Patients With Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - Prelude $145,112 3 payments
10. A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) $134,122 2 payments

1. Professional salary support $228,297 26 payments
2. Other $1,057 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.